Volume 14, Number 2—February 2008
Cost-effectiveness of Human Papillomavirus Vaccination in the United States
|Variable||Goldie et al. 2004 (10)||Sanders and Taira 2003 (11)||Taira et al. 2004 (13)||Elbasha et al. 2007 (9)|
|Key assumptions in published models|
|Target of HPV vaccine||HPV 16,18||High risk HPV types||HPV 16,18||HPV 6,11,16,18|
|Efficacy of vaccine||90%||75%||90%||100%‡|
|Vaccine cost per series||$393||$300||$300 + $100 booster||$360|
| Base year of $US
|Estimated cost per QALY of vaccination|
|Published model estimate||$24,300||$12,700§||$14,600||$3,000|
|Simplified model estimate||$20,600||$8,700||$17,100||$5,300|
*QALY, quality-adjusted life year; HPV, human papillomavirus.
†In all comparisons, the simplified model was modified (as necessary) so that the assumptions regarding the target of the HPV vaccine, vaccine efficacy and cost, vaccine duration of protection (except in the comparison to Taira and colleagues , as noted in the Technical Appendix, and the base year of US$ were consistent with the published models (Technical Appendix). The simplified model estimate was based on the cohort model in the comparisons with the findings of Goldie et al. (10) and Sanders and Taira (11) and was based on the population model (assuming transmission effects) in the comparison with the estimates of Taira and colleagues (13) and Elbasha and colleagues (9).
‡Elbasha and colleagues (9) assumed 90% protection against infection with HPV and 100% protection against HPV-related disease.§To enhance comparability, the published estimate from Sanders and Taira (11) was based on their sensitivity analyses when assuming lifetime duration of vaccination, not their base-case estimate of $22,800 when 10-y vaccine duration of protection was assumed.
- Institute of Medicine. Vaccines for the 21st century: a tool for decisionmaking. Washington: National Academy of Sciences; 2000.
- Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24(Suppl 3):S11–25.
- Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24.
- Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89:101–5.
- Dunne EF, Markowitz LE. Genital human papillomavirus infection. Clin Infect Dis. 2006;43:624–9.
- Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058–63.
- Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004;36:11–9.
- Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005;23:1107–22.
- Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28–41.
- Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96:604–15.
- Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37–48.
- Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781–9.
- Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915–23.
- Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88–100.
- Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
- Haddix AC, Teutsch SM, Corso PS, eds. Prevention effectiveness: a guide to decision analysis and economic evaluation, 2nd ed. New York: Oxford University Press; 2003.
- U.S. Census Bureau. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2005 (NC-EST2005–01). Population Division, US Census Bureau; 2006 [cited 2007 Aug 8]. Available from http://www.census.gov/popest/national/asrh/NC-EST2005-sa.html
- Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–51.
- Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18–27.
- Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–8.
- Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.
- US Cancer Statistics Working Group. United States cancer statistics: 2003 incidence and mortality. Atlanta: Centers for Disease Control and Prevention and National Cancer Institute; 2006.
- Hankey BF, Ries LA, Edwards BK. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev. 1999;8:1117–21.
- Watson M, Saraiya M, Weir H, Ahmed F. Leading partnerships to assess the burden of HPV-related cancers. 2007 CDC Cancer Conference Program of Events; 2007 Aug 13–17; Atlanta. Atlanta: Centers for Disease Control and Prevention; 2007. Abstract 005.
- Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191:105–13.
- Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397–403.
- Alam M, Stiller M. Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol. 2001;137:337–41.
- Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191:114–20.
- Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA. 1999;281:347–53.
- Maxwell GL, Carlson JW, Ochoa M, Krivak T, Rose GS, Myers ER. Costs and effectiveness of alternative strategies for cervical cancer screening in military beneficiaries. Obstet Gynecol. 2002;100:740–8.
- Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103:619–31.
- Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang Y, Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287:2372–81.
- Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Palefsky JM. Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. Am J Med. 2000;108:634–41.
- British Columbia Cancer Agency, Cancer Prevention Program. A population-based HPV immunization program in British Columbia: background paper. Vancouver (BC): The Agency; 2006.
- Lang K, Menzin J, Earle CC, Jacobson J, Hsu M. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg. 2004;130:1269–75.
- Gold MR, Franks P, McCoy KI, Fryback DG. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care. 1998;36:778–92.
- Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 2002;287:2382–90.
- Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111:145–53.
- Kulasingam SL, Myers ER, Lawson HW, McConnell KJ, Kerlikowske K, Meinikow J, Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol. 2006;107:321–8.
- Haupt RM. GARDASIL update. 2007 CDC Cancer Conference Program of Events; 2007 Aug 13–17; Atlanta. Atlanta: Centers for Disease Control and Prevention.